We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
Mylan NV said it will launch a formal offer worth about $33 billion in cash and stock to buy generic drug maker Perrigo Co.
Mylan, which had indicated earlier this month that it was considering such a bid, said its offer consists of $60 in cash and 2.2 Mylan shares for each share of Perrigo. Based on Thursday's close, the offer values Perrigo at about $222 a share.
Mylan shares have surged this month after the company received its own takeover approach from Teva Pharmaceutical Industries Ltd. worth about $40 billion.
Perrigo has thus far rejected Mylan's advance, and Mylan has spurned Teva.
The three-way tussle underscores the deal-making surge that is under way in an industry grappling with slowing growth. At the heart of the frenzy is a quest for new revenue amid pricing pressure from cash-strapped governments and insurers, and increased competition. Indeed, both EpiPen and Copaxone could face generic competition as soon as this year, analysts say.
Write to Angela Chen at angela.chen@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
